Need for Vitamin D in DLBCL
The effect of vitamin D deficiency (VDD) in elderly patients with diffuse large B-cell lymphoma (DLBCL) was examined.
Patients (n = 359) with pretreatment 25-hydroxyvitamin D3 (25[OH]D3) serum levels from the RICOVER-60 study and 63 patients from the RICOVER-noRTh study were investigated.
Patients form the RICOVER-60 study could receive rituximab; in the RICOVER-noRTh study, patients received two cycles of rituximab but no radiotherapy. Lactate dehydrogenase release assay of CD20+ Daudi cells was used to assess rituximab-mediated cytotoxicity (RMCC). Patients from the RICOVER-60 study with VDD (=8 ng/mL) and vitamin D levels =8 ng/mL treated with rituximab had a three-year event-free survival (EFS) of 59% and 79% and three-year overall survival (OS) of 70% and 82%, respectively. In multivariate analysis adjusting for International Prognostic Index risk factors these differences were significant with a hazard ratio of 2.1 (p = 0.008) for EFS and 1.9 (p = 0.040) for OS. In those not treated with rituximab, EFS was not significantly different in patients with vitamin D levels =8 ng/mL or =8 ng/mL. Following substitution and normalisation of vitamin D levels, RMCC increased significantly (p<0.001) in the seven patients with VDD. For more information, click here.